Throughout the years, people with diabetic macular oedema (DMO) have seen the number of options for their treatment increasing. Laser photocoagulation was the first of these and great experience is behind it; intraocular steroids followed and more recently anti-vascular endothelial growth factor (anti- VEGF) agents came to light. Ophthalmologists face now the dilemma of determining which may be the best therapeutic strategy for each particular patient based on best available evidence. This article summarises data available from randomised clinical trials (RCTs) on treatments for DMO and provides some facts about this condition and its treatments that need to be taken into consideration when treatment decisions are made.
Bibliographical notePublisher Copyright:
© 2018 AME Publishing Company. All rights reserved.
- Anti-vascular endothelial growth factor (anti-VEGF)
- Diabetic macular edema (DME)
- Diabetic macular oedema (DMO)
- Diabetic retinopathy
- Laser photocoagulation
- Randomised clinical trials (RCTs)
ASJC Scopus subject areas